NO20033883L - Heterosykliske derivater for behandling av kreft og andre proliferative sykdommer - Google Patents

Heterosykliske derivater for behandling av kreft og andre proliferative sykdommer

Info

Publication number
NO20033883L
NO20033883L NO20033883A NO20033883A NO20033883L NO 20033883 L NO20033883 L NO 20033883L NO 20033883 A NO20033883 A NO 20033883A NO 20033883 A NO20033883 A NO 20033883A NO 20033883 L NO20033883 L NO 20033883L
Authority
NO
Norway
Prior art keywords
cancer
treatment
proliferative diseases
heterocyclic derivatives
heterocyclic
Prior art date
Application number
NO20033883A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033883D0 (no
Inventor
Magnus Pfahl
Hussein A Al-Shamma
Andrea Fanjul
David P M Pleynet
Lyle W Spruce
Torsten R Wiemann
Jason B Ibarra
Catherine Tachdjian
Original Assignee
Incyte San Diego Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte San Diego Inc filed Critical Incyte San Diego Inc
Publication of NO20033883D0 publication Critical patent/NO20033883D0/no
Publication of NO20033883L publication Critical patent/NO20033883L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20033883A 2001-03-07 2003-09-02 Heterosykliske derivater for behandling av kreft og andre proliferative sykdommer NO20033883L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27475101P 2001-03-07 2001-03-07
PCT/US2002/007001 WO2002072009A2 (fr) 2001-03-07 2002-03-07 Derives heterocycliques pour le traitement du cancer et d'autres maladies proliferatives

Publications (2)

Publication Number Publication Date
NO20033883D0 NO20033883D0 (no) 2003-09-02
NO20033883L true NO20033883L (no) 2003-11-05

Family

ID=23049469

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033883A NO20033883L (no) 2001-03-07 2003-09-02 Heterosykliske derivater for behandling av kreft og andre proliferative sykdommer

Country Status (12)

Country Link
US (1) US7153875B2 (fr)
EP (1) EP1385465A4 (fr)
JP (1) JP2005506290A (fr)
AU (1) AU2002252227A1 (fr)
BR (1) BR0207846A (fr)
CA (1) CA2440184A1 (fr)
EA (1) EA200300982A1 (fr)
IL (1) IL157740A0 (fr)
MX (1) MXPA03008117A (fr)
NO (1) NO20033883L (fr)
PL (1) PL373912A1 (fr)
WO (1) WO2002072009A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0013671A (pt) 1999-08-31 2003-06-10 Maxia Pharmaceuticals Inc Derivados heterocìclicos para o tratamento do diabetes e outras doenças
WO2002072009A2 (fr) 2001-03-07 2002-09-19 Maxia Pharmaceuticals, Inc. Derives heterocycliques pour le traitement du cancer et d'autres maladies proliferatives
JP2004523571A (ja) 2001-03-08 2004-08-05 マキシア・ファーマシューティカルズ・インコーポレイテッド Ｒｘｒ活性化分子
JP2005500379A (ja) * 2001-08-17 2005-01-06 インサイト サンディエゴ インコーポレーテッド 異脂肪血症および高コレステロール血症を治療するオキシム誘導体
EP1456187A4 (fr) * 2001-11-15 2005-02-09 Incyte San Diego Inc Heterocycles n-substitues pour le traitement de l'hypercholesterolemie, de la dyslipidemie et autres troubles du metabolisme, du cancer et de pathologies diverses
CN100348569C (zh) 2001-11-30 2007-11-14 伯哈姆学院 癌细胞中编程性细胞死亡的诱导
US7102000B2 (en) * 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US7196108B2 (en) * 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
CA2520172C (fr) * 2003-03-27 2012-10-02 Lankenau Institute For Medical Research Nouvelles methodes pour le traitement du cancer avec un inhibiteur de l'indoleamine-2,3-dioxygenase
FR2856401B1 (fr) * 2003-06-20 2010-02-12 Galderma Res & Dev Nouveaux composes modulateurs des recepteurs de type ppargamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
DE10351744A1 (de) * 2003-10-31 2005-06-16 Schering Ag Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
US7122700B2 (en) 2004-07-30 2006-10-17 Xerox Corporation Arylamine processes
FR2884248B1 (fr) * 2005-04-08 2007-05-18 Galderma Res & Dev Nouveau procede de preparation de l'acide 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoique
KR101280779B1 (ko) * 2005-04-08 2013-07-05 갈데르마 리써어치 앤드 디벨로프먼트 6-(3-(1-아다만틸)-4-메톡시페닐)-2-나프토산의 신규 제조방법
KR100814109B1 (ko) 2006-01-09 2008-03-14 한국생명공학연구원 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물
TW200815429A (en) * 2006-04-11 2008-04-01 Smithkline Beecham Corp Thiazolidinedione derivatives as PI3 kinase inhibitors
US20080255115A1 (en) * 2007-04-11 2008-10-16 Michael Gerard Darcy Thiazolidinedione derivatives as pi3 kinase inhibitors
PE20090288A1 (es) * 2007-05-10 2009-04-03 Smithkline Beecham Corp Derivados de quinoxalina como inhibidores de la pi3 quinasa
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
EP2674417A3 (fr) 2007-11-21 2014-04-09 Decode Genetics EHF Inhibiteurs de pde4 biaryle pour le traitement de l'inflammation
AU2008326381B2 (en) * 2007-11-21 2014-10-23 Decode Genetics Ehf Biaryl PDE4 inhibitors for treating inflammation
CN102558088A (zh) * 2010-12-31 2012-07-11 中国科学院上海药物研究所 联苯亚甲基-2-硫代-4-噻唑酮类化合物及其制备方法和用途
KR102922092B1 (ko) * 2021-12-21 2026-02-03 주식회사 메디픽바이오 치환된 티아졸리딘디온 유도체 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물
US20250066347A1 (en) * 2021-12-21 2025-02-27 Medific, Inc. Substituted thiazolidinedione derivative compound, and pharmaceutical composition for preventing or treating cancer, comprising same
US12115148B1 (en) 2024-05-10 2024-10-15 Imam Mohammad Ibn Saud Islamic University 3-(2-(1,3-dioxoisoindolin-2-yl)ethyl)-5-(2-hydroxy-5-nitrobenzylidene)thiazolidine-2,4-dione as a potential antitumor and apoptotic inducer

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4051842A (en) 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (de) 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantierbare Dosiereinrichtung
JPS5538359A (en) 1978-09-12 1980-03-17 Hamari Yakuhin Kogyo Kk Preparation of 2-(3-benzoylphenyl)-propionic acid
US4383529A (en) 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
IL72684A (en) 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
US4713244A (en) 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
US4931279A (en) 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4668506A (en) 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
CA1325222C (fr) 1985-08-23 1993-12-14 Lederle (Japan), Ltd. Procede pour la production d'acide 4-biphenylylacetique
US4971996A (en) 1987-03-11 1990-11-20 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyrene compounds which are useful as tyrosine kinase inhibitors
FI91869C (fi) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
US5223522A (en) 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5330998A (en) 1988-03-08 1994-07-19 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
IE940525L (en) 1988-05-25 1989-11-25 Warner Lambert Co Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents
ES2123562T3 (es) 1991-07-22 1999-01-16 Pfizer Procedimiento para la preparacion de (s)-4-(3-(5-metil-2-fenil-4-oxazolil)-1-hidroxipropil)bromobenceno.
BR9306284A (pt) 1992-04-22 1998-01-13 Ligand Pharm Inc Compostos tendo seletividade pra receptores de retinóides x
US5780676A (en) 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
CZ181493A3 (en) 1992-09-10 1994-03-16 Lilly Co Eli The use of rhodanine derivative for the preparation of a pharmaceutical composition reducing level of sugar in blood and for treating alzheimer's disease
AU700706B2 (en) 1992-11-25 1999-01-14 Ligand Pharmaceuticals, Inc. RXR homodimer formation and bridged bicyclic aromatic compounds and their use in modulating gene expression
US5691376A (en) 1994-02-17 1997-11-25 American Home Products Corporation Substituted biphenyl derivatives
JPH09510191A (ja) 1994-02-17 1997-10-14 アメリカン・ホーム・プロダクツ・コーポレイション ホスホジエステラーゼ阻害薬としての置換ビフェニル誘導体
JPH09136877A (ja) 1995-06-16 1997-05-27 Takeda Chem Ind Ltd 複素環化合物、その製造法及び用途
CA2223489A1 (fr) 1995-07-17 1997-02-06 Joseph A. Fontana Procedes de traitement de cancers a l'aide de 6-¬3-¬1-adamantyl|-4-hydroxyphenyl|
CN1196730A (zh) 1996-06-19 1998-10-21 雷迪博士研究基金会 具有增强的抗糖尿病活性的穴糖酮的新的多晶型形式及其制备方法
RU2209626C2 (ru) 1996-07-08 2003-08-10 Галдерма Ресерч энд Девелопмент, С.Н.С. Производные адамантила, вызывающие апоптоз, и их использование в качестве противораковых агентов
EP1007038A2 (fr) 1997-08-21 2000-06-14 Takeda Chemical Industries, Ltd. Agent antiinflammatoire
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
JP4398585B2 (ja) 1997-11-12 2010-01-13 有限会社ケムフィズ レチノイドレセプター作用剤
US6262044B1 (en) 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
US6331633B1 (en) 1998-05-08 2001-12-18 Calyx Therapeutics Inc. Heterocyclic analogs of diphenylethylene compounds
ID27787A (id) 1998-08-21 2001-04-26 Viro Pharma Inc Senyawa, komposisi dan metode untuk pengobatan atau pencegahan infeksi yang disebabkan oleh virus dan penyakit-penyakit yang berkaitan
WO2000018748A1 (fr) 1998-09-30 2000-04-06 Roche Diagnostics Gmbh Derives de rhodanine utiles pour le traitement et la prevention de troubles metaboliques des os
WO2000032598A1 (fr) 1998-12-04 2000-06-08 Structural Bioinformatics Inc. Methodes et compositions destines au traitement de maladiesnflammatoires a base d'inhibiteurs de l'activite du facteur de necrose tumorale
WO2000063196A1 (fr) 1999-04-20 2000-10-26 Novo Nordisk A/S Nouveaux composes, leur preparation et leur utilisation
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
BR0013671A (pt) 1999-08-31 2003-06-10 Maxia Pharmaceuticals Inc Derivados heterocìclicos para o tratamento do diabetes e outras doenças
KR100608416B1 (ko) 1999-11-12 2006-08-02 후지모토 쿄다이 가부시키가이샤 2-(ｎ-시아노이미노)티아졸리딘-4-온 유도체
FR2812876B1 (fr) 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
WO2002072009A2 (fr) 2001-03-07 2002-09-19 Maxia Pharmaceuticals, Inc. Derives heterocycliques pour le traitement du cancer et d'autres maladies proliferatives
JP2004523571A (ja) 2001-03-08 2004-08-05 マキシア・ファーマシューティカルズ・インコーポレイテッド Ｒｘｒ活性化分子
CA2438586A1 (fr) 2001-03-14 2002-09-19 Eli Lilly And Company Modulateurs des recepteurs x de retinoides
CA2443325C (fr) 2001-04-04 2011-06-14 Ortho-Mcneil Pharmaceutical, Inc. Polytherapie comprenant des inhibiteurs de reabsorption du glucose et des modulateurs du recepteur x du retinoide
JP2005500379A (ja) 2001-08-17 2005-01-06 インサイト サンディエゴ インコーポレーテッド 異脂肪血症および高コレステロール血症を治療するオキシム誘導体
EP1456187A4 (fr) 2001-11-15 2005-02-09 Incyte San Diego Inc Heterocycles n-substitues pour le traitement de l'hypercholesterolemie, de la dyslipidemie et autres troubles du metabolisme, du cancer et de pathologies diverses
AR037714A1 (es) 2001-12-06 2004-12-01 Maxia Pharmaceuticals Inc Derivados de tiazolidinona y oxazolidinona 2-sustituidos para la inhibicion de fosfatasas y el tratamiento de cancer
US7102000B2 (en) 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
JP4638423B2 (ja) * 2003-06-20 2011-02-23 ガルデルマ・リサーチ・アンド・デヴェロップメント ＰＰＡＲγタイプ受容体を調節する新規化合物および化粧品組成物または医薬品組成物へのその使用

Also Published As

Publication number Publication date
EP1385465A2 (fr) 2004-02-04
CA2440184A1 (fr) 2002-09-19
MXPA03008117A (es) 2004-11-12
EP1385465A4 (fr) 2005-09-07
PL373912A1 (en) 2005-09-19
BR0207846A (pt) 2005-09-13
WO2002072009A3 (fr) 2003-10-16
US7153875B2 (en) 2006-12-26
US20020143182A1 (en) 2002-10-03
JP2005506290A (ja) 2005-03-03
IL157740A0 (en) 2004-03-28
NO20033883D0 (no) 2003-09-02
AU2002252227A1 (en) 2002-09-24
EA200300982A1 (ru) 2004-12-30
WO2002072009A2 (fr) 2002-09-19

Similar Documents

Publication Publication Date Title
NO20033883D0 (no) Heterosykliske derivater for behandling av kreft og andre proliferative sykdommer
CY2020005I1 (el) Παραγωγο ραπαμυκινης για τη θεραπευτικη αντιμετωπιση καρκινου του παγκρεατος
NO20052760D0 (no) Fremgangsmate for behandling av kreft og beslektede fremgangsmater.
NO20014560L (no) Quinasoliner og terapautisk anvendelse derav
NO20024610D0 (no) Synergistiske metoder og blandinger for behandling av kreft
NO20025792L (no) Kinazolinderivater for behandling av tumorer
NO20015516L (no) Preparater og anvendelser av ET743 for behandling av kreft
NO20031442L (no) Morfolin-acetamidderivater for behandling av inflammatoriske sykdommer
EE200300396A (et) Epotilooni derivaatide kasutamine refraktaarsete kasvajate raviks
NO20033682D0 (no) Epothilone-derivater for behandling av refraktor-tumorer
NO20034780D0 (no) Antiangiogenisk kombinasjonsterapi for behandling av kreft
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
NO20040516L (no) Kombinasjonsterapi for behandling av kreft.
EP1456187A4 (fr) Heterocycles n-substitues pour le traitement de l'hypercholesterolemie, de la dyslipidemie et autres troubles du metabolisme, du cancer et de pathologies diverses
NO20040726L (no) Kombinasjonspreparater av arylsubstituerte propanolaminderivater med andre aktive forbindelser og anvendelse derav.
NO20030748L (no) Prodruger av betulinsyrederivater for behandlingen av kreft og HIV
IS8125A (is) Kínasólínafleiður til að meðhöndla krabbamein
NO20024775D0 (no) Hydroksyfenyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
NO20041214L (no) Substituerte benzimidazolforbindelser og deres anvendelse for behandling av cancer
NO20020358D0 (no) Anvendelse av etodolac for behandling av kreft
NO20044250L (no) Heterocykliske amid-derivativer for behandling av diabetes og andre sykdommer
NO20055307D0 (no) Substituerte isokromanforbindelser for behandling av metabolske forstyrrelser, kreft og andre sykdommer
NO20024867D0 (no) Fremgangsmåte og preparat for behandling av kreft ved administrering av apoptoseinduserende kjemoterapeutiske midler
NO20033341D0 (no) Metoder for administrering av epothilone-analoger for behandling av kreft
NO20040059L (no) Benzo[G]kinolinderivater for behandling av glaukom og myopi

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application